The rising awareness about diabetes and kidney diseases has enhanced the demand for the market. The growing healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved point of care devices for diabetes also contributes to the rising demand for diabetes or HBA1C testing.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/saudi-arabia-turkey-and-egypt-hba1c-testing-market
Data Bridge Market Research analyses that the Saudi Arabia Hba1c Testing Market is expected to grow with a CAGR of 4.4% in the forecast period of 2023 to 2030 and is expected to reach USD 61.59 million by 2030 in Saudi Arabia and the Turkey hba1c testing market is expected to grow with a CAGR of 5.4% in the forecast period of 2023 to 2030 and is expected to reach USD 73.73 million by 2030 in Turkey and the Egypt hba1c testing market is expected to grow with a CAGR of 5.4% in the forecast period of 2023 to 2030 and is expected to reach USD 73.73 million by 2030 in E. The instruments segment is projected to propel the market growth as the development of advanced technologies
Strategic Initiatives by Key Market Players
Strategic initiatives such as acquisition, partnership, contract agreement, and participation in conferences provide an opportunity to flourish their customer base geographically. Both the market players open the door to additional or new resources such as technology and talent.
For instance,
- In March 2020, PTS Diagnostics recently announced that they would launch A1CNow+ Controls for the A1CNow+ Test System. A1CNow+ Controls are initially accessible in the US, EU, and UK. They can be kept frozen for up to three years, chilled for eight months, or at room temperature for seven days. The solution has two levels, each in a dropper-style vial, and may be effectively used in minutes. Its goal is to ensure accurate A1C findings.
Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the Saudi Arabia, Turkey & Egypt HbA1c Testing Market 2030
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2021 - 2014)
|
|
Quantitative Units
|
Revenue in USD million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Instruments, Reagents and Consumables), Mode of Testing (Prescription Based Testing and OTC Testing), Technology (Ion-exchange HPCL, Enzymatic Assay, Affinity Binding Chromatography, Turbidimetric Inhibition Immunoassay and Others), End User (Laboratories, Hospitals, Clinics, Homecare, Ambulatory Centres, Pharmacies/Drug Stores and Others), Distribution Channel (Third Party Distribution, Direct Sales and Retail Sales)
|
|
Countries Covered
|
Saudi Arabia, Turkey and Egypt
|
|
Market Players Covered
|
Siemens Healthcare GmbH, A. Menarini Diagnostics s.r.l , ARKRAY, Inc. , Trinity Biotech, Thermo Fisher Scientific Inc., Abbott, Wondfo, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, DxGen Corp. and among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, and regulatory framework.
|
Segment Analysis:
The Saudi Arabia, Turkey & Egypt HbA1c testing market is categorized into five segments: product type, mode of testing, technology, end user, and distribution channel.
- On the basis of product type, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into instruments, reagents, and consumables.
In 2023, the instruments segment is expected to dominate the market due to the rising demand for the point of care devices
In 2023, the instruments segment is expected to dominate the Saudi Arabia, Turkey, and Egypt HbA1c testing market due to rising demand for HbA1c testing & patient inclination towards point-of-care diagnosis with increasing awareness towards the disease.
- On the basis of mode of purchase, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into prescription based testing and OTC testing. In 2023, the prescription based testing segment is expected to dominate the Saudi Arabia, Turkey, and Egypt HbA1c testing market due to rising demand for prescription based HbA1c testing & patient inclination towards point-of-care diagnosis
- On the basis of technology, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into ion exchange HPCL, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay, and others. In 2023, the turbidimetric inhibition immunoassay segment is expected to dominate the market due to the rise in patient encouragement for the early detection or diagnosis of diabetes.
- On the basis of end user, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into laboratories, hospitals, clinics, homecare, ambulatory centers, pharmacies/drug stores and others. In 2023, the laboratories segment is expected to dominate the Saudi Arabia, Turkey, and Egypt HbA1c testing market due to rise in R&D activities with new advancements in the devices getting approvals from authorized bodies to commercialize the products.
- On the basis of distribution channel, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into third party distribution, direct sales, and retail sales. The retail sales segment is further segmented into online pharmacy, hospital pharmacy, and others. In 2023, the direct sales segment is expected to dominate the Saudi Arabia, Turkey, and Egypt HbA1c testing market due to the rising demand for HbA1c testing in Saudi Arabia, Turkey & Egypt.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the the Saudi Arabia, Turkey, and Egypt HbA1c testing market that include Siemens Healthcare GmbH, A. Menarini Diagnostics s.r.l , ARKRAY, Inc. , Trinity Biotech, Thermo Fisher Scientific Inc., Abbott, Wondfo, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, DxGen Corp. and among others.
Market Development
- In September 2020, Roche Diabetes Care got approval for the certification of all of Roche Diabetes Care's Class I medical devices in its diabetes care portfolio to the Medical Device Regulation was completed. Roche formally pledges to ensure that all of its Class I medical devices in its diabetes care portfolio—i.e., low-risk for patients insertion devices and lancing devices-comply with the MDR's requirements by signing the EU Declarations of Conformity.
- In May 2019, Siemens Healthineers AG launched the new Atellica CH Enzymatic Hemoglobin A1c (A1c E) Test to help clinicians identify and monitor diabetes, a rising and potentially fatal condition. In its clinical laboratory and point-of-care solutions, Siemens Healthineers offers a selection of HbA1c assays for diagnosing diabetes. The corporation has increased the variety of its products as a result.
- In March 2020, PTS Diagnostics recently announced that they would launch A1CNow+ Controls for the A1CNow®+ Test System. A1CNow+ Controls are initially accessible in the US, EU, and UK. They can be kept frozen for up to three years, chilled for eight months, or at room temperature for seven days. The solution has two levels, each in a dropper-style vial, and may be effectively used in minutes. Its goal is to ensure accurate A1C findings.
- In March 2023, Abbott announced a definitive agreement with Cardiovascular Systems, Inc. (CSI), a manufacturer of medical devices with a cutting-edge atherectomy system used to treat peripheral and coronary artery disease, under which Abbott would purchase CSI. Abbott's market-leading vascular device lineup will gain access to fresh, complementary innovations thanks to the purchase of CSI. This has caused the business to grow for the corporation.
Regional Analysis
Geographically, the countries covered in the transfection reagents and equipment market report are Saudi Arabia, Turkey and Egypt
As per Data Bridge Market Research analysis:
Turkey is the dominant country in Saudi Arabia, Turkey, and Egypt HbA1c testing market during the forecast period 2023-2030
In 2023, Turkey dominated the product type segment and increasing prevalence of diabetes worldwide. Turkey will continue to dominate the Saudi Arabia, Turkey, and Egypt HbA1c testing market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and launch of new products in this country. Additionally, the increasing number of cases of diabetes problems and the rising development of point of care devices are expected to further enhance the market's growth rate in the country.
For more detailed information about the Saudi Arabia, Turkey, and Egypt HbA1c testing market report, click here - https://www.databridgemarketresearch.com/jp/reports/saudi-arabia-turkey-and-egypt-hba1c-testing-market
